Stimulation of lymphocyte anti-melanoma activity by co-cultured macrophages activated by complex homeopathic medication.
BACKGROUND
Melanoma is the most aggressive form of skin cancer, and the most rapidly expanding cancer in terms of worldwide incidence. Chemotherapeutic approaches to treat melanoma have been uniformly disappointing. A Brazilian complex homeopathic medication (CHM), used as an immune modulator, has been recommended for patients with depressed immune systems. Previous studies in mice have demonstrated that the CHM activates macrophages, induces an increase in the number of leukocytes and improves the murine response against Sarcoma-180.


METHODS
Here we studied the interaction of mouse lymph node lymphocytes, co-cultured in vitro with macrophages in the presence or absence of the CHM, with B16F10 melanoma cells.


RESULTS
Lymphocytes co-cultured with macrophages in the presence of the CHM had greater anti-melanoma activity, reducing melanoma cell density and increasing the number of lysed tumor cells. There was also a higher proportion of activated (CD25+) lymphocytes with increased viability. Overall, lymphocytes activated by treatment destroyed growing cancer cells more effectively than control lymphocytes.


CONCLUSIONS
Co-culture of macrophages with lymphocytes in the presence of the CHM enhanced the anti-cancer performance of lymphocytes against a very aggressive lineage of melanoma cells. These results suggest that non-toxic therapies using CHMs are a promising alternative approach to the treatment of melanomas. In addition, they are attractive combination-therapy candidates, which may enhance the efficacy of conventional medicines by improving the immune response against tumor cells.
Guimarães
Fernando S F
FS
Departamento de Biologia Celular, Laboratório de Pesquisa em Células Inflamatórias e Neoplásicas, Universidade Federal do Paraná (UFPR), Curitiba - PR, Brazil. ferbiocel@yahoo.com.br
Abud
Ana P R
AP
Oliveira
Simone M
SM
Oliveira
Carolina C
CC
César
Beatriz
B
Andrade
Lucas F
LF
Donatti
Lucélia
L
Gabardo
Juarez
J
Trindade
Edvaldo S
ES
Buchi
Dorly F
DF
D000818:Animals; D045744:Cell Line, Tumor; D002478:Cells, Cultured; D018920:Coculture Techniques; D003602:Cytotoxicity, Immunologic; D008214:Lymphocytes / Q000187:drug effects* / Q000276:immunology; D008262:Macrophage Activation / Q000187:drug effects; D008264:Macrophages / Q000187:drug effects* / Q000276:immunology; D008297:Male; D008419:Materia Medica / Q000494:pharmacology*; D008545:Melanoma / Q000188:drug therapy / Q000276:immunology*; D051379:Mice
D008419:Materia Medica
Homeopathy. 2005 Jan;94(1):26-32
15751331
Clin Cancer Res. 2006 May 15;12(10):3130-6
16707612
Eur J Cancer. 2006 Apr;42(6):745-50
16517151
Oncol Res. 2006;16(5):211-6
17294801
Annu Rev Immunol. 2006;24:175-208
16551247
Cancer Cell. 2002 Sep;2(3):169-71
12242147
Cytokine Growth Factor Rev. 2003 Oct;14(5):361-8
12948519
CA Cancer J Clin. 2000 Jul-Aug;50(4):215-36; quiz 237-40
10986965
J Submicrosc Cytol Pathol. 2002 Jul;34(3):255-63
12408358
J Cell Biochem. 2008 Jul 1;104(4):1364-77
18286468
Cell. 2002 Jun 14;109(6):707-18
12086670
Micron. 2008 Jun;39(4):461-70
17379529
Eur J Cancer. 2001 Sep;37(13):1709-18
11527700
Science. 2002 Oct 25;298(5594):850-4
12242449
Mol Cell Biochem. 2003 Nov;253(1-2):339-45
14619985
Nat Immunol. 2001 Jun;2(6):487-92
11376334
Cytokine Growth Factor Rev. 2002 Apr;13(2):169-83
11900992
Nat Rev Immunol. 2003 Jan;3(1):23-35
12511873
Immunol Lett. 2006 Aug 15;106(2):135-43
16769127
Eur J Cancer. 2006 Feb;42(3):282-9
16376071
Genet Mol Res. 2003 Jun 30;2(2):223-8
14966688
Nat Immunol. 2001 Jul;2(7):585-9
11429541
Cell Struct Funct. 1993 Dec;18(6):399-407
8033221
Lancet. 2005 Feb 19-25;365(9460):687-701
15721476
Micron. 2006;37(3):277-87
16364649
J Am Coll Surg. 2005 Sep;201(3):418-25
16125076
Cell Biol Int. 2006 Oct;30(10):808-16
16884931
J Infect. 2006 Jun;52(6):420-32
16386798
J Infect. 2005 Aug;51(2):157-64
16038768